+0.35 %
-10.34 %
-13.27 %
-14.74 %
-78.70 %
-79.25 %
-88.39 %
-90.24 %
-87.27 %
Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.
Read moreMarket cap
96.85M EUR
Turnover
37.48K EUR
P/E (adj.) (26e)
-4.73
EV/EBIT (adj.) (26e)
-3.84
P/B (26e)
22.15
EV/S (26e)
21,696.87
Dividend yield-% (26e)
-
